Rifampin isoniazid dosage and administration: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Rifampin isoniazid }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RIFAMATE (RIFAMPIN AND ISONIAZID)...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Dosage and Administration== | |||
In general, therapy should be continued until bacterial conversion and maximal improvement have occurred. | |||
===Adults=== | |||
Two RIFAMATE (rifampin and isoniazid capsules USP) capsules (600 mg rifampin, 300 mg isoniazid) once daily, administered one hour before or two hours after a meal. | |||
Concomitant administration of [[pyridoxine]] (B6) is recommended in the malnourished, in those predisposed to [[neuropathy]] (e.g., diabetic), and in adolescents.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RIFAMATE (RIFAMPIN AND ISONIAZID) CAPSULE [SANOFI-AVENTIS U.S. LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3cc36609-8e2d-4caa-a8e0-c0367e3e52df | publisher = | date = | accessdate }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RIFAMATE (RIFAMPIN AND ISONIAZID) CAPSULE [SANOFI-AVENTIS U.S. LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3cc36609-8e2d-4caa-a8e0-c0367e3e52df | publisher = | date = | accessdate }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 18:02, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Dosage and Administration
In general, therapy should be continued until bacterial conversion and maximal improvement have occurred.
Adults
Two RIFAMATE (rifampin and isoniazid capsules USP) capsules (600 mg rifampin, 300 mg isoniazid) once daily, administered one hour before or two hours after a meal.
Concomitant administration of pyridoxine (B6) is recommended in the malnourished, in those predisposed to neuropathy (e.g., diabetic), and in adolescents.[1]
References
- ↑ "RIFAMATE (RIFAMPIN AND ISONIAZID) CAPSULE [SANOFI-AVENTIS U.S. LLC]". Text " accessdate " ignored (help)
Adapted from the FDA Package Insert.